These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21076630)

  • 1. Achieving lipid targets in adults with type 2 diabetes: the Stop Atherosclerosis in Native Diabetics Study.
    Russell M; Silverman A; Fleg JL; Lee ET; Mete M; Weir M; Wilson C; Yeh F; Howard BV; Howard WM
    J Clin Lipidol; 2010; 4(5):435-43. PubMed ID: 21076630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.
    Fleg JL; Mete M; Howard BV; Umans JG; Roman MJ; Ratner RE; Silverman A; Galloway JM; Henderson JA; Weir MR; Wilson C; Stylianou M; Howard WJ
    J Am Coll Cardiol; 2008 Dec; 52(25):2198-205. PubMed ID: 19095139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German-Austrian diabetes registry.
    Brandts J; Tittel SR; Bramlage P; Danne T; Brix JM; Zimny S; Heyer CHJ; Holl RW; Müller-Wieland D
    Diabetes Obes Metab; 2023 Dec; 25(12):3700-3708. PubMed ID: 37694759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
    Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.
    Morrone D; Weintraub WS; Toth PP; Hanson ME; Lowe RS; Lin J; Shah AK; Tershakovec AM
    Atherosclerosis; 2012 Aug; 223(2):251-61. PubMed ID: 22410123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.
    Simons L; Tonkon M; Masana L; Maccubbin D; Shah A; Lee M; Gumbiner B
    Curr Med Res Opin; 2004 Sep; 20(9):1437-45. PubMed ID: 15383192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes.
    Rotella CM; Zaninelli A; Le Grazie C; Hanson ME; Gensini GF
    Lipids Health Dis; 2010 Jul; 9():80. PubMed ID: 20663203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experience.
    Mete M; Wilson C; Lee ET; Silverman A; Russell M; Stylianou M; Umans JG; Wang W; Howard WJ; Ratner RE; Howard BV; Fleg JL
    J Diabetes Complications; 2011; 25(6):362-7. PubMed ID: 21775166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Screening for hyperlipidemia in cardiovascular high-risk patients in austrian diabetes ambulances].
    Brath H; Wascher TC; Kästenbauer T; Toplak H
    MMW Fortschr Med; 2012 Jun; 154 Suppl 2():41-7. PubMed ID: 23424754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-release niacin or ezetimibe and carotid intima-media thickness.
    Taylor AJ; Villines TC; Stanek EJ; Devine PJ; Griffen L; Miller M; Weissman NJ; Turco M
    N Engl J Med; 2009 Nov; 361(22):2113-22. PubMed ID: 19915217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid and cardiometabolic features of T2DM patients achieving stricter LDL-C and non-HDL-C targets in accordance with ESC/EAS 2019 guidelines.
    Hermans MP; Ahn SA; Rousseau MF
    Acta Cardiol; 2021 Jun; 76(4):375-383. PubMed ID: 32202204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
    Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
    Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
    Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
    Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes.
    Torimoto K; Okada Y; Mori H; Hajime M; Tanaka K; Kurozumi A; Narisawa M; Yamamoto S; Arao T; Matsuoka H; Inokuchi N; Tanaka Y
    Lipids Health Dis; 2013 Sep; 12():137. PubMed ID: 24053480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of lower targets for blood pressure and low-density lipoprotein cholesterol in diabetes: the Stop Atherosclerosis in Native Diabetics Study (SANDS) .
    Wilson C; Huang CC; Shara N; Howard BV; Fleg JL; Henderson JA; Howard WJ; Huentelman H; Lee ET; Mete M; Russell M; Galloway JM; Silverman A; Stylianou M; Umans J; Weir MR; Yeh F; Ratner RE
    J Clin Lipidol; 2010; 4(3):165-72. PubMed ID: 20563294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.